GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Orum Therapeutics 475830.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

14,420

-1.23%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩23.6m

FY2022FY2025

Net income

−₩41.97bn

FY2022FY2025

Free cash flow

−₩36.68bn

FY2022FY2025

Shareholders' equity

₩130.89bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩23.6m₩20.91bn₩135.42bn₩75.9m
Gross profit₩23.6m₩20.91bn₩135.42bn₩75.9m
Research and development₩35.65bn₩17.04bn₩18.71bn₩33.17bn
Operating income−₩51.76bn−₩8.34bn₩95.61bn−₩43.65bn
Net income−₩41.97bn−₩5.74bn₩68.22bn−₩63.32bn
Diluted earnings per share-1,976.66-274.273,259.44-3,025.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩169.32bn₩153.84bn₩161.78bn₩21.28bn
Cash and short-term investments—₩117.70bn₩126.66bn₩12.09bn
Total liabilities₩38.44bn₩32.07bn₩217.96bn₩148.74bn
Debt—₩28.33bn₩211.26bn₩140.74bn
Shareholders' equity₩130.89bn₩121.76bn−₩56.18bn−₩127.46bn
Shares outstanding21m21m21m21m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−₩35.99bn−₩11.28bn₩94.24bn−₩41.09bn
Capital spending−₩696.3m−₩1.26bn−₩1.13bn−₩796.1m
Free cash flow−₩36.68bn−₩12.55bn₩93.12bn−₩41.89bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩24.1m—₩558,170₩15.9m₩4.2m₩3.0m₩2.5m₩20.87bn
Gross profit₩24.1m—₩558,170₩15.9m₩4.2m₩3.0m₩2.5m₩20.87bn
Operating income−₩15.35bn−₩18.08bn−₩18.25bn−₩13.94bn−₩10.00bn−₩9.57bn−₩7.91bn₩12.78bn
Net income₩63.38bn−₩15.28bn−₩15.97bn−₩13.62bn−₩3.77bn−₩8.60bn−₩10.89bn₩14.43bn
Diluted earnings per share2,985.27-719.56-752.38-643.73-179.05-410.92-520.20689.46
Cash from operations−₩18.96bn−₩15.34bn−₩11.60bn−₩6.26bn−₩10.82bn−₩7.31bn−₩11.28bn−₩1.29bn
Capital spending−₩108.0m−₩50.0m−₩265.0m−₩157.0m−₩195.0m−₩77.0m−₩1.26bn−₩770.0m
Free cash flow−₩19.07bn−₩15.39bn−₩11.87bn−₩6.42bn−₩11.01bn−₩7.39bn−₩12.54bn−₩2.06bn
Total assets₩291.99bn₩312.82bn₩169.32bn₩182.33bn₩185.73bn₩191.52bn₩153.84bn₩159.94bn
Cash and short-term investments—————₩158.45bn₩117.70bn₩124.18bn
Debt—————₩23.95bn₩207.8m₩23.21bn
Shareholders' equity₩186.00bn₩119.57bn₩130.89bn₩145.18bn₩157.19bn₩161.79bn₩121.76bn₩130.82bn

Financial ratios

Data as of 27 Aug 2026

FY2025FY2024FY2023FY2022
Gross margin100.0%100.0%100.0%100.0%
Operating margin-219651.5%-39.9%70.6%-57492.6%
Net margin-178105.4%-27.5%50.4%-83402.6%
Return on equity-32.1%-4.7%-121.4%49.7%
Return on assets-24.8%-3.7%42.2%-297.5%
Revenue growth-99.9%-84.6%178270.5%—
Earnings growth631.2%-108.4%-207.7%—
Current ratio8.61x3.84x0.66x0.09x
Debt to equity—0.00x0.00x-0.01x
Equity ratio77.3%79.2%-34.7%-598.9%
Interest coverage-27.50x-4.65x115.98x-579.10x
R&D as a share of sales151300.2%81.5%13.8%43689.1%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-32.3%——
Operating income5.8%——
Net income-12.8%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%100.0%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-60.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.